VC  TIO Bioventures

https://tiobioventures.com/





     Office Locations:

411 Lafayette St, 6th Floor
New York, NY 10003

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Early
  • Growth


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    TIO Bioventures is a boutique venture creation firm focused on funding the advancement of biotechnology companies that are guided by its principles of employing research-driven science to create first-in-class cancer medicines. Unlike a traditional venture fund, TIO Bioventures leverages its internal TIO Discovery to provide R&D and management services to its portfolio companies. To date, the majority of financing for TIO Discovery and TIO portfolio company drug discovery and development efforts has come from non-dilutive funds from philanthropic and competitive grant awards, such as those from the Canadian Foundation for Innovation, the collaborative funding partnership between The California Institute for Regenerative Medicine (CIRM) and the Cancer Stem Cell Consortium (CSCC), and the Princess Margaret Hospital (PMH) Foundation. In 2020, the firm will close their first fund, TIO Bioventures Fund I.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Mark Bray PhD Partner
    Rachel W. Humphrey MD Head of R&D
    Ryan Dietz JD Partner
    Shane Burgess OD, MBA CEO & Managing Director
    Tak Wah Mak PhD Co-Founder & Managing Director

     

    Portfolio companies include:

     

    Recent News: